Chiaching Wang, MD
Internal Medicine · San Francisco, CANPI 1922260520
Payments from drug & device makers
What this record shows
This record is dominated by education: $434 of the $545 with a category attached, or 79.7%. Pfizer accounts for 69.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $367 and has fallen 55.4% since, to $164 in 2025.
Across 17 payments — averaging $32.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$381
- Genentech, Inc.$164
Across 2 payments — averaging $280,026 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$560K
What the payments were for
- Food & beverage$11120%
- Education$43480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $381 |
| Genentech, Inc. | 2 | $164 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$545 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 14 | $211,106 |
| Aprepitant | 14 | $4,677 |
| Abiraterone Acetate | 13 | $3,802 |
| Lamivudine HbvLamivudine | 13 | $2,923 |
| Ondansetron Hcl | 41 | $313 |
| Dexamethasone | 24 | $283 |
| LoperamideLoperamide Hcl | 11 | $116 |
| Prednisone | 13 | $97 |
| Olanzapine | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.